Anaplastic thyroid cancer

AffyImmune Therapeutics Awarded Best Oncology R&D Advance Scrip Award 2023

Retrieved on: 
Friday, November 17, 2023
Anaplastic thyroid cancer, Safety, Therapy, Cancer, Pharmaceutical industry, Nursing, Scrip

NATICK, Mass. and LONDON, Nov. 17, 2023 /PRNewswire/ -- AffyImmune Therapeutics, Inc., a clinical stage biotechnology company finding safe, effective ways to use CAR T cells against solid tumors, was awarded the first-ever Best Oncology R&D Advance at the 2023 Scrip Awards. This new Scrip Award recognizes early clinical advances in oncology made by small biopharmaceutical companies across the globe. AffyImmune topped the list of six finalists deemed to be pioneering new approaches in the treatment of cancer that have shown proof of concept in early clinical trials and have candidates moving forward in the development pathway.

Key Points: 
  • and LONDON, Nov. 17, 2023 /PRNewswire/ -- AffyImmune Therapeutics, Inc., a clinical stage biotechnology company finding safe, effective ways to use CAR T cells against solid tumors, was awarded the first-ever Best Oncology R&D Advance at the 2023 Scrip Awards .
  • This new Scrip Award recognizes early clinical advances in oncology made by small biopharmaceutical companies across the globe.
  • "We're thrilled to receive the award, especially in an impressive group of finalists this year; this award is a recognition of the hard work of the AffyImmune team," Chief Operating Officer Matt Britz said.
  • We truly appreciate the confirmation from Scrip and the exposure for our candidate which we believe could greatly improve patient outcomes."

AffyImmune Therapeutics Named 2023 Scrip Award Finalist for Best Oncology R&D Advance

Retrieved on: 
Thursday, September 21, 2023
Anaplastic thyroid cancer, CAR, Cancer, Therapy, Patient, Pharmaceutical industry

NATICK, Mass., Sept. 21, 2023 /PRNewswire/ -- AffyImmune Therapeutics, Inc., a clinical stage biotechnology company finding safe, effective ways to use CAR T cells against solid tumors, has been recognized as a Scrip Award finalist for the first-ever Best Oncology R&D Advance award. This new Scrip Award recognizes early clinical advances in oncology made by small biopharmaceutical companies across the globe. AffyImmune is one of six finalists whose pioneering new approaches in the treatment of cancer have shown proof of concept in early clinical trials and who have candidates moving forward in the development pathway.

Key Points: 
  • NATICK, Mass., Sept. 21, 2023 /PRNewswire/ -- AffyImmune Therapeutics, Inc., a clinical stage biotechnology company finding safe, effective ways to use CAR T cells against solid tumors, has been recognized as a Scrip Award finalist for the first-ever Best Oncology R&D Advance award.
  • This new Scrip Award recognizes early clinical advances in oncology made by small biopharmaceutical companies across the globe.
  • AffyImmune Chief Operating Officer Matt Britz stated "It's an honor to be part of this remarkable group of global finalists.
  • Winners of each of the fourteen Scrip Awards will be announced in November 2023.

Jason Colodne and Colbeck Capital Support the MD Anderson Cancer Center at the University of Texas in Connection With Its Anaplastic Thyroid Cancer Research

Retrieved on: 
Tuesday, August 22, 2023
Biotechnology, Banking, Professional Services, Health, General Health, Pharmaceutical, Oncology, Research, Science, Clinical Trials, Finance, Survival, University, University of Texas at Austin, Cancer, ATC, MD Anderson Cancer Center, Education, Anaplastic thyroid cancer, Patient, Thyroid cancer, Pharmaceutical industry

Jason Colodne and Colbeck Capital Management (“Colbeck”) today announced their continued support of the MD Anderson Cancer Center at The University of Texas, one of the world’s most respected centers devoted exclusively to cancer patient care, research, education, and prevention, in connection with the center’s research to combat Anaplastic Thyroid Cancer (“ATC”).

Key Points: 
  • Jason Colodne and Colbeck Capital Management (“Colbeck”) today announced their continued support of the MD Anderson Cancer Center at The University of Texas, one of the world’s most respected centers devoted exclusively to cancer patient care, research, education, and prevention, in connection with the center’s research to combat Anaplastic Thyroid Cancer (“ATC”).
  • ATC is the most advanced and aggressive form of thyroid cancer and one of the fastest growing cancers, most commonly found in people over the age of 60.
  • Although less than 2% of patients with thyroid cancer have ATC, it is known as one of the most lethal malignancies with a current 5-year survival rate of 7%, accounting for approximately 40% of all thyroid cancer–related mortalities.
  • MD Anderson Cancer Center’s mission is to eliminate cancer in Texas, the nation, and the world through outstanding programs that integrate patient care, research, and prevention, and through education for undergraduate and graduate students, trainees, professionals, employees, and the public.

Latest Vitrakvi® (larotrectinib) Subgroup Analyses at ASCO 2023 Showcase Long-Term Efficacy and Safety Profile in Adult and Pediatric Patients with NTRK Gene Fusion Cancer, Across Solid Tumors

Retrieved on: 
Friday, June 2, 2023
General Health, Pharmaceutical, Health, Oncology, Hypersensitivity, DTC, IRC, Central nervous system, NGS, Trae tha Truth, Lung cancer, Mutation, NTRK1, CNS, ASCO, Bayer, Food and Drug Administration Amendments Act of 2007, American Society of Clinical Oncology, Dor, Myalgia, Patient, Data, NTRK, Anemia, Annual general meeting, Disease, Anaplastic thyroid cancer, ALT, ATC, FDA, AST, Society, NTRK2, Thyroid cancer, ORR, TC, Food, Safety, TRK, Pharmaceutical industry

The data was presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting from June 2-6, 2023.

Key Points: 
  • The data was presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting from June 2-6, 2023.
  • Patients should be selected for therapy based on a Food and Drug Administration (FDA)-approved test.
  • The results encourage wider adoption of next-generation sequencing (NGS) testing for identifying patients with solid tumors harboring NTRK gene fusions, including lung cancer.
  • Vitrakvi was evaluated in updated subgroup analyses of patients (n=30; data cut-off July 20, 2022) with TRK fusion thyroid cancer (TC).

AffyImmune Therapeutics Announces Positive Safety and Early Efficacy Results from Phase 1 Study of AIC100 CAR T Cells in Anaplastic and Advanced Thyroid Cancers at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

Retrieved on: 
Thursday, May 25, 2023
PDTC, MB, CRS, Anaplastic thyroid cancer, DL2, Haematopoietic system, MD Anderson Cancer Center, ASCO, CAR, Assistant professor, American Society of Clinical Oncology, Cytokine release syndrome, Patient, Division, University, Annual general meeting, Neoplasm, Toxic epidermal necrolysis, Infrared spectroscopy correlation table, ATC, Therapy, Society, Thyroid, SD, Safety, Pharmaceutical industry, Vaccine, Bachelor of Medicine, Bachelor of Surgery

"This is an important clinical milestone for AffyImmune as we continue to develop AIC100 in the clinic and explore additional solid tumor indications with high unmet need."

Key Points: 
  • "This is an important clinical milestone for AffyImmune as we continue to develop AIC100 in the clinic and explore additional solid tumor indications with high unmet need."
  • The current Phase 1 study is exploring three dose levels (DL) of AIC100 CAR T cells, which are developed using AffyImmune's proprietary Tune & Track CAR T cell platform.
  • To date, AIC100 CAR T cells demonstrated excellent safety and encouraging efficacy in anaplastic (ATC) and poorly differentiated (PDTC) thyroid cancers.
  • Early results from the Phase 1 study include:
    No DLTs were reported; two patients had transient grade 1 CRS.

F-star Therapeutics Announces Publication of Phase 1 Dose-Escalation Trial of FS118 in Patients with Advanced Cancer and PD-L1 Resistance in Clinical Cancer Research

Retrieved on: 
Monday, November 7, 2022
Patient, Private Securities Litigation Reform Act, Universal asynchronous receiver-transmitter, Population, Securities Exchange Act of 1934, University, Research, Seven Seas, CNS, TIME, Annual report, Clinical Cancer Research, Technology, SEC, Company, Infrared spectroscopy correlation table, American Association for Cancer Research, GLOBE, Sino Biopharmaceutical Limited, Schedule, MD Anderson Cancer Center, Forward-looking statement, PSLRA, DCR, Drug development, Cancer, Drug discovery, Maintenance, Nasdaq, Letter, Terminology, Anaplastic thyroid cancer, Personal Information Agent, PD-L1, Immunotherapy, American Association, Therapy, Time, CD137, Patent, COMMON, Safety, Downregulation and upregulation, IO, Pharmacology, NASDAQ, Risk, Association, Communication, Pharmaceutical industry, Vaccine

CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX) (“F-star” or the “Company”), a clinical-stage biopharmaceutical company pioneering bispecific antibodies for immunotherapy so more people with cancer can live longer and improved lives, today announced the publication of safety and efficacy results from Phase 1 trial of FS118 in patients with advanced cancer and PD-L1 resistance in Clinical Cancer Research, a journal of the American Association for Cancer Research.

Key Points: 
  • Phase 1 data published in Clinical Cancer Research demonstrate that FS118 has the potential to overcome cancer immune resistance given the prolonged pharmacodynamic activity, said Louis Kayitalire, Chief Medical Officer of F-star.
  • We look forward to generating additional data and leveraging our bispecific approach to provide therapies for patients with advanced cancer.
  • Weekly administration was well tolerated, with no dose-limiting toxicities (DLTs), and no serious adverse events (SEAs) relating to FS118.
  • In the Phase 1 clinical trial, FS118 was well tolerated with no treatment-related serious adverse events and no dose-limiting toxicity, up to 20mg/kg.

AffyImmune Therapeutics' AIC100 Granted Fast Track Designation for Treating Thyroid Cancer

Retrieved on: 
Monday, May 17, 2021
Anatomy, Food and Drug Administration, Life sciences, Branches of biology, Fast track, Anaplastic thyroid cancer, Thyroid, Pembrolizumab

b'NATICK, Mass., May 17, 2021 /PRNewswire/ -- AffyImmune Therapeutics, Inc., a clinical stage biotechnology company finding safe, effective ways to use CAR T cells against solid cancers, announced today that the US Food and Drug Administration (FDA) granted Fast Track designation to its lead compound, AIC100, for the treatment of anaplastic thyroid cancer and refractory poorly differentiated thyroid cancer.

Key Points: 
  • b'NATICK, Mass., May 17, 2021 /PRNewswire/ -- AffyImmune Therapeutics, Inc., a clinical stage biotechnology company finding safe, effective ways to use CAR T cells against solid cancers, announced today that the US Food and Drug Administration (FDA) granted Fast Track designation to its lead compound, AIC100, for the treatment of anaplastic thyroid cancer and refractory poorly differentiated thyroid cancer.
  • The company previously received Orphan Drug designation for AIC100.\nThe FDA\'s Fast Track designation is designed to facilitate development and expedite review of drug candidates to treat serious conditions and address an unmet medical need.
  • Receipt of Fast Track designation provides grounds for more frequent interaction with the FDA throughout the drug development process for more rapid advancement, earlier approval and access for patients.\n"We are pleased to have received Fast Track designation for our first-in-human CAR T cell product currently being tested in patients with refractory thyroid cancer," remarked Eric von Hofe, President and COO of AffyImmune.
  • "It highlights the unmet need in treating refractory solid tumors and points to the potential of AIC100 to address that need.

The anaplastic thyroid cancer drugs market at a CAGR of more than 4% during the forecast period

Retrieved on: 
Tuesday, July 2, 2019
Glands, Organ systems, RTT, Medicine, Thyroid disease, Thyroid cancer, Anaplastic thyroid cancer, Oncology, Thyroid, Chemotherapy, Treatment of cancer, Cancer

Global Anaplastic Thyroid Cancer Drugs Market: About this market

Key Points: 
  • Global Anaplastic Thyroid Cancer Drugs Market: About this market
    Our anaplastic thyroid cancer drugs market analysis considers sales from both chemotherapy and novel therapy.
  • Also, our global anaplastic thyroid cancer drugs market report looks at factors such as the introduction of targeted therapies, and the rising geriatric population and high prevalence of thyroid cancer.
  • Global anaplastic thyroid cancer drugs market: Overview
    The adverse effects associated with the off-label medicines available in the market has led to the development of targeted therapies for cancer treatments.
  • For the detailed list of factors that will drive the global anaplastic thyroid cancer drugs market during the forecast period 2019-2023, click here.

Global Anaplastic Thyroid Cancer Drugs Market 2019-2023 | Presence of Reimbursement Policies for Chemotherapy to Boost the Market | Technavio

Retrieved on: 
Friday, June 14, 2019
Health, Oncology, Pharmaceutical, Organ systems, Medicine, RTT, Clinical medicine, Thyroid disease, Anaplastic thyroid cancer, Thyroid cancer, Chemotherapy, Thyroid, Doxorubicin

View the full release here: https://www.businesswire.com/news/home/20190614005209/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20190614005209/en/
    Technavio has published a new market research report on the global anaplastic thyroid cancer drugs market from 2019-2023.
  • Global anaplastic thyroid cancer drugs market: Presence of reimbursement policies for chemotherapy
    Chemotherapeutics such as doxorubicin, cisplatin, and paclitaxel are the most commonly used off-label therapies for the treatment of anaplastic thyroid cancer.
  • Therefore, the presence of reimbursement policies for chemotherapy will positively impact the anaplastic thyroid cancer drugs market growth during the forecast period.
  • Global anaplastic thyroid cancer drugs market: Segmentation analysis
    This market research report segments the global anaplastic thyroid cancer drugs market by product (chemotherapy, and novel therapy), and geographic regions (North America, Europe, Asia, and ROW).

Anaplastic Thyroid Cancer - Pipeline Insight, 2019 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, April 24, 2019
Health, Pharmaceutical, Glands, Human anatomy, RTT, Anatomy, Thyroid disease, Thyroid cancer, Thyroid, Anaplastic thyroid cancer, Drug pipeline, Cancer

The "Anaplastic Thyroid Cancer - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Anaplastic Thyroid Cancer - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • The report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Anaplastic Thyroid Cancer development.
  • The report covers pipeline activity across the complete product development cycle i.e.
  • clinical, pre-clinical and discovery stages for Anaplastic Thyroid Cancer
    The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information
    Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Anaplastic Thyroid Cancer
    Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine